Samantha Sollitto Journalism Portfolio

A federal judge from Texas ruled the Food and Drug Administration’s 23-year-old approval of mifepristone invalid on April 7. Shortly afterward, a conflicting ruling in favor of the pill was made in a federal court in Washington state, placing the decision in the hands of the Supreme Court. 

But leaving the fate of mifepristone’s accessibility up to the high court is probably more dangerous to the well-being of women across America than the pill itself.